DiaSorin S.p.A. (LON:0GZX)

Market Cap	2.98B -32.7%
Revenue (ttm)	1.06B +2.7%
Net Income	160.70M -2.5%
EPS	2.98
Shares Out	n/a
PE Ratio	18.57
Forward PE	15.21
Dividend	1.01 (1.47%)
Ex-Dividend Date	May 19, 2025

Volume	8,335
Average Volume	16,315
Open	64.67
Previous Close	64.78
Day's Range	63.28 - 65.64
52-Week Range	58.14 - 101.40
Beta	0.62
RSI	31.37
Earnings Date	Mar 20, 2026

About DiaSorin

DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, endocrinology, gastrointestinal infections, autoimmunity, hypertension, emergency/sepsis, bone metabolism, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urin...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1968
• Employees: 3,242
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0GZX

Financial Performance

In 2024, DiaSorin's revenue was 1.19 billion, an increase of 3.24% compared to the previous year's 1.15 billion. Earnings were 188.11 million, an increase of 17.68%.

Financial numbers in EUR